0000000001018471

AUTHOR

A Miceli

showing 2 related works from this author

PROBIOTICI E TERAPIA CONVENZIONALE: NUOVE FRONTIERE NELLA GESTIONE DELLE MANIFESTAZIONI ARTICOLARI DELLE MALATTIE INFIAMMATORIE INTESTINALI (IBD)

2014

Summary: This work reports a clinical trial performed at palermo University Hospital "paolo Giaccone". From January 2004 to December 2011, 79 patients were enrolled (40 men and 39 women). All patients suffered from Inflammatory Bowel Disease (IBD) and were subjected to orthopedic consultation at the institute of Orthopaedics, University Hospital of palermo, for arthropathy to IBD. The patients were divided into two groups (A and B) and dealt with different therapies for the resolution of the inflammatory picture of the colonic mucosa and the treatment of the extraintestinal articular manifestations. Group A was treated with drug therapy: Diclofenac (75 mg im/ day for 10 days9 and Mesalazine…

Settore MED/18 - Chirurgia GeneraleSettore MED/12 - GastroenterologiaSettore MED/09 - Medicina InternaSettore BIO/16 - Anatomia UmanaIntestinal Bowel Disease probiotics extraintestinal manifestationf ob IBD
researchProduct

Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistr…

2017

BACKGROUND: Older patients are prone to multimorbidity and polypharmacy, with an inherent risk of adverse events and drug interactions. To the best of our knowledge, available information on the appropriateness of lipid-lowering treatment is extremely limited. AIM: The aim of the present study was to quantify and characterize lipid-lowering drug use in a population of complex in-hospital older patients. METHODS: We analyzed data from 87 units of internal medicine or geriatric medicine in the REPOSI (Registro Politerapie della Società Italiana di Medicina Interna) study, with reference to the 2010 and 2012 patient cohorts. Lipid-lowering drug use was closely correlated with the clinical prof…

Malemedicine.medical_specialtyLogistic ModelLipid-Lowering AgentsPopulationSocio-culturaleOlder Hospitalized Patients030204 cardiovascular system & hematologyGeriatrics and Gerontology; Pharmacology (medical)03 medical and health sciences0302 clinical medicineInternal medicine80 and overPrevalencemedicineHumansPharmacology (medical)030212 general & internal medicineMedical prescriptionIntensive care medicineOmega 3 fatty acideducationAdverse effectAgedHypolipidemic AgentsAged 80 and overPolypharmacyGeriatricseducation.field_of_studyHypolipidemic Agentbusiness.industryGeriatrics and Gerontology Pharmacology (medical)HospitalizationLogistic ModelsCohortPolypharmacyAged; Aged 80 and over; Female; Hospitalization; Humans; Hypolipidemic Agents; Logistic Models; Male; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)FemaleGeriatrics and GerontologybusinessAged; Aged 80 and over; Female; Hospitalization; Humans; Hypolipidemic Agents; Logistic Models; Male; Polypharmacy; PrevalenceHumanCohort study
researchProduct